
Hepanova, Inc.: A global pharmaceutical firm innovating therapeutics for chronic liver diseases since 2014.
Hepanova, Inc. is a clinical-stage global pharmaceutical company founded in California, USA, in 2014. Its core mission is to discover, develop, and commercialize innovative therapeutics for chronic liver diseases with high unmet medical needs. The company's product pipeline focuses on addressing conditions such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma (HCC).
Notable affiliated people and investors include leading figures in the pharmaceutical and biotech industries, although specific names are not publicly disclosed. Key achievements include advancing multiple R&D programs through various stages of clinical trials, demonstrating significant potential in treating chronic liver conditions. Hepanova's impact lies in its commitment to providing groundbreaking treatments that could significantly improve patient outcomes in the realm of liver diseases.

Hepatx
hepatx.com

Bluejay Therapeutics
bluejaytx.com

Intercept Pharmaceuticals

Inipharm
inipharm.com

Enanta Pharmaceuticals
enanta.com

Chromis Therapeutics

Enavate Sciences

MediciNova
medicinova.com

Neurana Pharmaceuticals
neuranapharma.com

Novoron Bioscience
novoron.com

Seranova Bio
seranovabio.com

Innoviva
inva.com

Ribonova
ribonova.com

NanoPharmaceuticals

Reven Holdings
reven.com
Companies similar to Hepanova include Hepatx, Bluejay Therapeutics, Intercept Pharmaceuticals and Inipharm.
Hepanova was founded in 2014.
Hepanova's headquarters is located in Gaithersburg, MD, US.
Hepanova's most recent funding round was for $1.8M (USD) in April 2023.
As of Apr 15, 2023, Hepanova has raised a total of $10.2M (USD).
Hepanova has 11 employees as of Feb 5, 2024.